The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

It targets two hormone receptors, GIP and GLP-1. Semgalutide, known as Ozempic for diabetes and Wegovy for weight loss, is also part of this broad class of drugs.

By Maggie Fick and Louise Rasmussen Sept 20 (Reuters) - Swiss medical technology company Ypsomed YPSN.S announced on Wednesday a long-term supply deal with Novo Nordisk NOVOb.CO for autoinjectors ...

It targets two hormone receptors, GIP and GLP-1. Semgalutide, known as Ozempic for diabetes and Wegovy for weight loss, is also part of this broad class of drugs.